# Native and SEPIO-based Representation of CIViC EID879 record.
# Illustrates the SEPIO model for curation of evidence lines (evaluating data as evidence for a target proposition, absent a materialized Asserton). 


##------------------------------------------------------------------------------------------------------------##


# The *original* CIViC json data for EID879 (core evidence-related content only - lifecycle actions, assertions removed for now)
# Data pulled from https://civicdb.org/api/evidence_items/879
{

    "id": 879,
    "name": "EID879",
    "description": "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).",
    "disease": {
        "id": 30,
        "name": "Lung Adenocarcinoma",
        "display_name": "Lung Adenocarcinoma",
        "doid": "3910",
        "url": "http://www.disease-ontology.org/?id=DOID:3910"
    },
    "drugs": [
        {
            "id": 146,
            "name": "Afatinib",
            "ncit_id": "C66940",
            "aliases": [
                "BIBW2992",
                "BIBW 2992",
                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide"
            ]
        }
    ],
    "rating": 4,
    "evidence_level": "B",
    "evidence_type": "Predictive",
    "clinical_significance": "Sensitivity/Response",
    "evidence_direction": "Supports",
    "variant_origin": "Somatic",
    "drug_interaction_type": null,
    "status": "accepted",
    "open_change_count": 0,
    "type": "evidence",
    "source": {
        "id": 592,
        "name": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.",
        "citation": "Sequist et al., 2013, J. Clin. Oncol.",
        "citation_id": "23816960",
        "source_type": "PubMed",
        "asco_abstract_id": null,
        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23816960",
        "open_access": null,
        "pmc_id": null,
        "publication_date": {
            "year": 2013,
            "month": 9,
            "day": 20
        },
        "journal": "J. Clin. Oncol.",
        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "status": "fully curated",
        "is_review": false,
        "clinical_trials": [
            {
                "nct_id": "NCT00949650",
                "name": "BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation",
                "description": "This randomised, open label phase III trial will be performed in patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation. The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A, with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of patients.",
                "clinical_trial_url": "https://clinicaltrials.gov/show/NCT00949650"
            }
        ]
    },
    "flagged": false,
    "variant_id": 33,
    "phenotypes": [ ],
    "updated_at": "2020-08-12T15:43:10.010Z",

}

##---------------------------------------------------------------------------------------------------------------------##


# A proposed VA-SEPIO representation of this data (as a yaml rendering of json). 
# Uses four objects - an Evidence Line, Proposition, Evidence Item, and Publication)


# EVIDENCE LINE -  The message is rooted at the Evidence Line object - as this is what is being curated in this workflow.
  - id: civic-data:EID879    # "civic-data:" is a temp namespace for all identifiers minted by CIViC for entities they create in their dataset
    type: EvidenceLine       
    evaluated_proposition: civic-data:Proposition001      # the Proposition against which the evidence is evaluated
    evidence_direction:      # this field takes a 'Coding' data type (a complex data type used to hold the iri and label of coded/enumerated values)
      - id: civic-term:002   # "civic-term:" is a temp namespace for all identifiers minted by civic for enumerated terms used in their dataset
        label: supports
    evidence_strength:  
      - id: civic-term:001   
        label: B
    has_evidence_item:  civic-data:EvItem001        # the Evidence Item / Study Result that is evaluated as evidence
    qualified_contributions: [civic-data:Contribution001, civic-data:Contribution002, ... ]  # To Do 

 
# EVALUATED PROPOSITION (the target proposition representing the 'possible fact' that evidence was evaluated against to generate the Evidence Line
  - id: civic-data:Proposition001
     type: TherapeuticResponseProposition   # a specialization of VA-SEPIO 'Proposition'
     subject: civic-data:33                 # EGFR L858R. This will ultimately be a GKS VariationDescriptor.
     predicate:
       - id: ex:001                         # ideally this coded value will come from an external, established community terminology or code set. 
         label: predicts_sensitivity_to
     object:
       - id: civic-data:146
         type: TherapeuticIntervention      # the VA-SEPIO domain entity mapping to CIViC:TherapyProfile
         label: Afatinib 
     treated_condition_qualifier:
       - id: civic-data:30
         type: GeneticCondition             # the VA-SEPIO domain entity mapping to CIViC:Disease
         disease:
           - DOID:3910
             label: Lung Adenocarcinoma
         url: "http://www.disease-ontology.org/?id=DOID:3910
     allele_origin_qualifier: 
       - id: GENO:0000882 
         label: somatic allele origin

# EVIDENCE ITEM (a StudyResult object)
  - id: civic-data:EvItem001  # A new id may have to be minted if we split apart the EID object into its Evidence Line and Evidence Item components.
    type: StudyResult         # VA-SEPIO object representing a curated collection/description of data from a Study that focuses on a subset/perspective of interest (e.g. results relevant for a particular interrogated variant)
    focus: civic-data:33      # The specific focus of this Study Result is to describe data relevant to the EGFR L858R variant
    description: "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001)."
    confidence_level: 
      - id: civic-term:003 
        label: 4-star
    reference: civic-source:592   # the Publication / Source that provided the data described in the Study Result
         
# Examples of additional structured fields that could be split out if we wanted to explicitly represent individual data items from the Study Result.
#   study_size: 308         
#   median_PFS_afatinib: 13.6 months
#   median_PFS_chemotherapy: 6.9 months
#   hazard_ratio: 0.47; 95% CI, 0.34 to 0.65
#   p-value: 0.001
           
           
# PUBLICATION (the source of data used as evidence)  VA-SEPIO has not (yet) defined a rich model to capture Publication info/metadata. A few basic fields can capture the info below.  
  - id: civic-data:592 
    type: Publication   
    identifier:            # VA-SEPIO follows the FHIR model for distinguishing logical vs business identifiers, using a complex 'Identifier' data type for the latter
      - value: 25923549    # we will likely want to consider going with a CURIE structure for identifiers here
        system: PMID          
    label: "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations."
    url: "http://www.ncbi.nlm.nih.gov/pubmed/23816960"    
     


##----------------------------------------------------------------------------------------------------------##


# CIVIC Assertion6 (AID6) record (which points to the Evidence above as support) - https://civicdb.org/events/assertions/6/summary
# Uses Propositions to capture Assertion semantics, and the evaluated target of Evidence Lines
# Assertion states that "EGFR L858R (somatic) predicts sensitivity to Afatinib treatment of NSCLC".

  - id: civic-data:AID6
    type: TherapeuticResponseStatement 
    description: "EGFR L858R positive NSCLC is sensitive to afatinib."     
    asserted_proposition: civic-data:Proposition001
    has_evidence_line: civic-data:EID879  
    was_specified_by: [civic-data:method_1, civic-data:method_2] 
    confidence_level: Tier I - Level A 
    
# ASSERTED PROPOSITION (the claim that is put forth as true in Assertion AID6)
  - id: civic-data:Proposition001
    type: TherapeuticResponseProposition          # A specialization of VA-SEPIO 'Proposition'
    subject: civic-data:33                        # EGFR L858R. This will ultimately be a VRS object / descriptor. 
    predicate: predicts_sensitivity_to  
    object:
      - id: civic-data:drug_146                   
        type: TherapeuticIntervention   
        label: Afatinib 
    allele_origin_qualifier: 
      - id: GENO:0000882 
        label: somatic allele origin
    treated_condition_qualifier:
      - id: civic-data:disease_8
        type: GeneticCondition   
        disease:            
          - DOID:3908    
            label: Lung Non-small Cell Carcinoma
            url: "http://www.disease-ontology.org/?id=DOID:3908   

# EVIDENCE LINE
  - id: civic-data:EID879    
    type: EvidenceLine       
    evaluated_proposition: civic-data:Proposition002      # the Proposition against which the evidence is evaluated
    evidence_direction:      
      - id: civic-term:002   
        label: supports
    evidence_strength:  
      - id: civic-term:001   
        label: B
    has_evidence_item:  civic-data:EvItem001              # the Evidence Item / Study Result that is evaluated as evidence
    qualified_contributions: [civic-data:Contribution001, civic-data:Contribution002, ... ]  # To Do 

 
# EVALUATED PROPOSITION (the 'possible fact' that evidence was evaluated against to generate the Evidence Line)
  - id: civic-data:Proposition002           # NOTE this is DIFFERENT from the asserted Proposition in the root Assertion (disease is more specific)
     type: TherapeuticResponseProposition   
     subject: civic-data:33                 
     predicate:
       - id: ex:001                        
         label: predicts_sensitivity_to
     object:
       - id: civic-data:146
         type: TherapeuticIntervention      
         label: Afatinib 
     treated_condition_qualifier:
       - id: civic-data:30
         type: GeneticCondition           
         disease:        # The disease here is a descendent of disease int he asserted Proposition (Lung Non-small Cell Carcinoma)
           - DOID:3910
             label: Lung Adenocarcinoma
         url: "http://www.disease-ontology.org/?id=DOID:3910
     allele_origin_qualifier: 
       - id: GENO:0000882 
         label: somatic allele origin


# EVIDENCE ITEM  (a StudyResult object)
  - id: civic-data:EvItem001  
    type: StudyResult         
    focus: civic-data:33      
    description: "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001)."
    confidence_level: 
      - id: civic-term:003 
        label: 4-star
    reference: civic-source:592   
          
           
# PUBLICATION (the source of data used as evidence)    
  - id: civic-data:592 
    type: Publication   
    identifier:            
      - value: 25923549 
        system: PMID          
    label: "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations."
    url: "http://www.ncbi.nlm.nih.gov/pubmed/23816960"   


# METHODS
  - id: civic-data:method_1         
    type: VariantInterpretationGuideline
    label: Non-Small Cell Lung Cancer (v3.2018) 

  - id: civic-data:Method_2 
    type: EvidenceLevelGuideline
    label: AMP-ASCO-CAP Guidelines
    reference: PMID: 27993330










    has_evidence_line: 
      - id: civic-data:EID879    
        type: EvidenceLine       
        evidence_direction:     
          - id: civic-term:002   
            label: supports
        evidence_strength:  
          - id: civic-term:001   
            label: B
        has_evidence_item:         # here we represent info about the study result that the Evidence Line above interprets/evaluates as evidence
         - id: civic-data:EI001 
           type: StudyResult    
           description: "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001)."
           confidence_level: 
             - id: civic-term:003 
               label: 4-star
           reference:        
             - id: civic-data:592 
               type: Publication   
               identifier:         # VA-SEPIO follows the FHIR model for distinguishing logical vs business ids, using a 'Identifier' data type for the latter
                 - value: 25923549    
               system: PMID          
               label: "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations."
               url: "http://www.ncbi.nlm.nih.gov/pubmed/23816960"   
